HRAS/KRAS/NRAS Recombinant Monoclonal Antibody

The RAS family of small GTPases—comprising HRAS, KRAS, and NRAS—represents one of the most intensively studied signaling nodes in cell biology. These molecular switches cycle between active GTP-bound and inactive GDP-bound states to regulate cell proliferation, differentiation, and survival through the MAPK and PI3K pathways. With RAS mutations present in approximately 30% of human cancers, reliable detection of these proteins remains essential for researchers investigating oncogenic signaling, therapeutic resistance mechanisms, and normal cellular physiology.

This recombinant monoclonal antibody, clone 6B2, offers the consistency and reproducibility that RAS pathway research demands. Developed using recombinant technology with a defined sequence, it eliminates the lot-to-lot variability that can compromise longitudinal studies and multi-site collaborations. The rabbit IgG format, raised against a synthetic peptide conserved across human HRAS, KRAS, and NRAS, enables simultaneous detection of all three isoforms—particularly valuable when studying total RAS activity or compensatory expression patterns.

Western blot validation demonstrates robust performance across diverse experimental systems, detecting the expected 22 kDa band in human colorectal cancer lines SW620 and HT29, T-cell leukemia line Jurkat, HeLa cervical carcinoma, and HEK293 cells. Cross-species reactivity extends to mouse samples, confirmed in NIH/3T3 fibroblasts. Flow cytometry validation in HepG2 hepatocellular carcinoma cells shows clear separation from isotype controls, supporting intracellular staining applications for single-cell analysis of RAS expression.

Whether you're characterizing RAS-driven tumor models, validating CRISPR knockouts, or profiling pathway activation states, this antibody provides the specificity and flexibility to support your experimental workflow across Western blot, flow cytometry, and ELISA platforms.